Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis
目的探讨咪唑立宾（mizoribine,MZR）治疗儿童紫癜性肾炎的安全性及疗效。方法纳入33例紫癜性肾炎（Ⅱb级）患儿,按其治疗方案不同分为2组:治疗组18例给予口服咪唑立宾片治疗(剂量2.5～3 mg·kg<sup>-1</sup>·d<sup>-1</sup>),治疗3个月后逐渐减量。对照组15例给予口服泼尼松片(1 mg·kg<sup>-1</sup>·d<sup>-1</sup>)联合吗替麦考酚酯片(剂量20～30 mg·kg<sup>-1</sup>·d<s...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2019-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57913934&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849728883876691968 |
|---|---|
| author | 丁娟娟 栾江威 戚畅 潘德华 |
| author_facet | 丁娟娟 栾江威 戚畅 潘德华 |
| author_sort | 丁娟娟 |
| collection | DOAJ |
| description | 目的探讨咪唑立宾（mizoribine,MZR）治疗儿童紫癜性肾炎的安全性及疗效。方法纳入33例紫癜性肾炎（Ⅱb级）患儿,按其治疗方案不同分为2组:治疗组18例给予口服咪唑立宾片治疗(剂量2.5～3 mg·kg<sup>-1</sup>·d<sup>-1</sup>),治疗3个月后逐渐减量。对照组15例给予口服泼尼松片(1 mg·kg<sup>-1</sup>·d<sup>-1</sup>)联合吗替麦考酚酯片(剂量20～30 mg·kg<sup>-1</sup>·d<sup>-1</sup>),治疗3个月后逐渐减量。两组疗程均为9～12个月,观察两组血常规、尿常规、24 h尿蛋白定量、血清白蛋白、肝肾功能及药物不良反应。结果治疗后,治疗组与对照组临床总有数率相当。两组治疗后24 h尿蛋白定量均低于治疗前,血清白蛋白水平均高于治疗前,差异有统计学意义（P<0.05）,血丙氨酸转氨酶、血肌酐及血尿酸变化差异无统计学意义（P>0.05）。治疗组仅有2例在治疗初期出现轻微皮疹的不良反应。对照组不良反应有上呼吸道感染3例,白细胞下降3例,腹泻1例,恶心、呕吐1例。结论 MZR治疗临床表现为中度蛋白尿的紫癜性肾炎患儿,具有一定临床疗效,其疗效与泼尼松联合吗替麦考酚酯片相当,但其治疗更为简单经济、不良反应少,为儿童紫癜性肾炎的治疗提供了一种新的方案。 |
| format | Article |
| id | doaj-art-ad13e81d308541109ffca9a68e2b923a |
| institution | DOAJ |
| issn | 1671-2390 |
| language | zho |
| publishDate | 2019-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj-art-ad13e81d308541109ffca9a68e2b923a2025-08-20T03:09:25ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902019-01-0120821057913934Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis丁娟娟栾江威戚畅潘德华目的探讨咪唑立宾（mizoribine,MZR）治疗儿童紫癜性肾炎的安全性及疗效。方法纳入33例紫癜性肾炎（Ⅱb级）患儿,按其治疗方案不同分为2组:治疗组18例给予口服咪唑立宾片治疗(剂量2.5～3 mg·kg<sup>-1</sup>·d<sup>-1</sup>),治疗3个月后逐渐减量。对照组15例给予口服泼尼松片(1 mg·kg<sup>-1</sup>·d<sup>-1</sup>)联合吗替麦考酚酯片(剂量20～30 mg·kg<sup>-1</sup>·d<sup>-1</sup>),治疗3个月后逐渐减量。两组疗程均为9～12个月,观察两组血常规、尿常规、24 h尿蛋白定量、血清白蛋白、肝肾功能及药物不良反应。结果治疗后,治疗组与对照组临床总有数率相当。两组治疗后24 h尿蛋白定量均低于治疗前,血清白蛋白水平均高于治疗前,差异有统计学意义（P<0.05）,血丙氨酸转氨酶、血肌酐及血尿酸变化差异无统计学意义（P>0.05）。治疗组仅有2例在治疗初期出现轻微皮疹的不良反应。对照组不良反应有上呼吸道感染3例,白细胞下降3例,腹泻1例,恶心、呕吐1例。结论 MZR治疗临床表现为中度蛋白尿的紫癜性肾炎患儿,具有一定临床疗效,其疗效与泼尼松联合吗替麦考酚酯片相当,但其治疗更为简单经济、不良反应少,为儿童紫癜性肾炎的治疗提供了一种新的方案。http://www.lcszb.com/thesisDetails?columnId=57913934&Fpath=home&index=0咪唑立宾紫癜儿童治疗 |
| spellingShingle | 丁娟娟 栾江威 戚畅 潘德华 Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis Linchuang shenzangbing zazhi 咪唑立宾 紫癜 儿童 治疗 |
| title | Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis |
| title_full | Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis |
| title_fullStr | Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis |
| title_full_unstemmed | Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis |
| title_short | Clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis |
| title_sort | clinical efficacy of mizoribine tablets for treatment of pediatric purpura nephritis |
| topic | 咪唑立宾 紫癜 儿童 治疗 |
| url | http://www.lcszb.com/thesisDetails?columnId=57913934&Fpath=home&index=0 |
| work_keys_str_mv | AT dīngjuānjuān clinicalefficacyofmizoribinetabletsfortreatmentofpediatricpurpuranephritis AT luánjiāngwēi clinicalefficacyofmizoribinetabletsfortreatmentofpediatricpurpuranephritis AT qīchàng clinicalefficacyofmizoribinetabletsfortreatmentofpediatricpurpuranephritis AT pāndéhuá clinicalefficacyofmizoribinetabletsfortreatmentofpediatricpurpuranephritis |